Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Shanxi Tianyu Pharmaceutical Co.

PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Developer of medicines for treatment of sclerosis. The company mainly produces Lauromacrogol API and Lauromacrogol Injection, which are surgical medication for treatment of sclerosis. Its other products include sodium carbonate oral tonic and CoQ10 soft capsules. Its core technology is Lauromacrogol synthesis and its Lauromacrogol API and Lauromacrogol Injection own fully independent intellectual property rights in China.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • The hi tech Zone of Xi'an city
  • Road two No. 68 Software Park A block 3F
  • Xi’an
  • China

+86 029 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Shanxi Tianyu Pharmaceutical Co.’s full profile, request a free trial.

Shanxi Tianyu Pharmaceutical Co. Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Shanxi Tianyu Pharmaceutical Co. Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Jun Yuan Capital Venture Capital Minority 000 0000 000000 0